Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Joan B. Fowler, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Presenters:
Floor J. Backes, MD–has disclosed that she is a consultant for Clovis and TESARO, Inc. She receives grant/research support from Clovis.
Heather Dalton, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ursula A. Matulonis–has disclosed that she is a consultant for FUJIFILM, Geneos, Immunogen, Merck, and Mersana. She receives grant/research support from Merck.
Bradley J. Monk, MD, FACS, FACOG—has disclosed that he is a consultant for Abbvie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis, Conjupro, Genmab, Gradalis, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson & Johnson, Mateon, Merck, Myriad, Perthera, Pfizer, Precison Oncology, Puma, Roche/Genentech, Samumed, Takeda, Tesaro, Inc., and VBL. He also is a member of the speakers’ bureaus for AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, and Tesaro, Inc.
Kathleen N. Moore, MD, MS–has disclosed that she is a consultant for Aravive, AstraZeneca, Clovis, Genentech/Roche, Immunogen, Janssen, Merck, OncoMed, Pfizer, Samumed, and Tesaro. She receives grant/research support from Genentech/Roche, Lilly, and PTC Therapeutics.
Shannon N. Westin, MD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Lyndsay J. Willmott, MD, FACOG–has disclosed that she is a member of the speakers’ bureaus for Clovis, Merck, and TESARO, Inc.

Reviewers:
Gabriela Lacatus, RN, BSN, OCN, PhD–has no relevant financial relationships to disclose in relation to the content of this activity.
Shannon N. Westin, MD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Margaret K. Wilson, MMS, PA-C–has no relevant financial relationships to disclose in relation to the content of this activity.